Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

i am one of the buys . wish i had got in when shares tipped them a few weeks ago . it does look very exciting at the moment.looking for 20p by christmas.

Bosley I bought them the first week shares recommeded them and I also topped up today, up 0.63p looking good so far!! Fingers crossed and all the best!!

lets hope as oakapples says that the price movement this week is not anticipating a positive statement that never happens.on a more positive note any good news could take the share price a long way

Rumour circulating their could be an annoucement on Monday. Hence the volume buying this week.

Does anyone know for sure, is there going to be an anouncement tomorrow???

Probably not imho

momentum - wrong!!!!!

I want to know though despite the lioss announced - why is it that there is no 'momentum' off the back of the phase iii results - are [people expecting the worst or have they deliberately delayed the results of the trials to sogften the blow from the financials?

CeNeS Pharmaceuticals PLC
20 September 2004


CeNeS Reports 2004 Interim Results

Cambridge, UK 20 September 2004 - CeNeS Pharmaceuticals plc (AIM: CEN) ('CeNeS'
or 'the Company') today announced its unaudited interim financial results for
the six months ended 30 June 2004.


Operational highlights

M6G successfully completes Phase III trial in post-operative pain (see
separate press release dated today)
CNS 5161 for neuropathic pain entered a Phase II trial.


Financial highlights

Net loss for the first half of 2004 of 2.3m (H1 2003: profit 0.9m
including 3.2m profit on sale of pharmaceutical products).
Cash balances at end of June 2004 of 6.1m (June 2003: 8.2m).


Corporate matters

Alan Smith, Chairman of Acambis Plc and Avlar Bioventures Limited
appointed as a Non-executive Director.
Piper Jaffray Ltd and Nomura International plc appointed nominated
advisor (NOMAD) and nominated broker respectively.



Commenting on the results, Alan Goodman, Chairman of CeNeS Pharmaceuticals plc,
said:


'The Board is delighted to report that CeNeS has continued to successfully meet
its key strategic objectives in 2004.


We are particularly pleased with the announcement today of the positive M6G
Phase III results in post-operative pain. CeNeS retains all global marketing
rights to M6G and is well placed to capture the potential commercial value in
this novel, late stage pain product.

Additionally, CNS 5161 has commenced a Phase II trial in neuropathic pain with
patient recruitment underway. Furthermore, the Company's pre-clinical short
acting sedative and discovery Parkinson's disease programmes are also
progressing in line with expectations. CeNeS owns the global rights to all three
of these programmes.

There is a significant opportunity for CeNeS in realising the clinical and
commercial potential of M6G as an effective analgesic with a good side effect
profile. In light of these positive results the Company is considering its
financing options for taking this product forward, including equity funding and/
or out-licensing.

Overall, CeNeS is building a balanced, focused pipeline which is being
effectively managed by our in-house experts as evidenced by the successful
clinical progress we have made. CeNeS is also encouraged by additional novel
early stage opportunities that are being identified by our discovery team that
fit our focused 'risk-reduced' selection criteria.


The Board is confident that the Company's clear strategic focus coupled with the
excellent progress made to date in 2004 leaves CeNeS well placed to deliver
increased value to shareholders going forward.'



Contact details:

FOR TODAY ONLY:
Mary Clark - Capital MS&L - 0207 903 1000.

After today contact details are:

CeNeS Pharmaceuticals plc
Alan Goodman/Neil Clark
Tel: +44 (0)1223 266466
Fax: +44 (0)1223 266467
Capital MS&L

Mary Clark/Paula Crymble
Tel: +44 (0)20 7878 3181
Fax: +44 (0)20 7878 3184

Review of the six months ended 30 June 2004

what exactly were people expecting from the results? as far as i read it . they dont really have any products on the market , so no revenue , but good potential products have just successfully gone through trials and could be on the market by next year . this is a buy and hold .

B_R

Don't think it really matters. All people will see today are the losses. Results of the Phase III trials although very good news will not generate any income until 2005/2006. CENES is a long term hold, those in now or at lower levels will reap the rewards later, but unfortunately these lower levels may be around for a little while yet, hence the selling. Hang on if you have the patience. All IMHO of course, DYOR etc etc.

Regards

PTH

looking at trades so far today it seems this was one of those , buy on rumour sell on news type, investments .

Just giving these two announcements a little more thought; Classic piece of bad PR. The losses have grabbed the headlines and the Phase III trials are forgotten. Perhaps they should have released the results, let the SP take the hit and then release the good news three or four days later, probably restoring the SP value. Just a thought, never mind, not long until 2006!!

regards

PTH

Taken a hard hit this morning, tend to think it may be this that as spooked holders....................

"In light of these positive results the Company is considering its
financing options for taking this product forward, including equity funding and/
or out-licensing.". Dilution in one form or another. They were looking very good, perhaps we may get a quick recovery. Dont hold but have been tempted.

cheers GF.

might be a good time to get in gf.

I have taken my profits and run (a little reluctantly!) - but I will be back - if it drops to 9p IMHO it will bounce back

tipped again as a buy in shares mag this week . started to creep back up . looks like people have seen the potential. bad pr excersise making the two announcements together i think.

The words to use are not ' bad PR exercise' - amateurish is more like it,
prices move on perception, they need to be a lot slicker about the way they put across news.

Re post 61 - It did and I did - Is it a bit of a worry that Shares Mag recommend it 3 weeks out of 4 ?

Good write up in the Times today, puts into perspective the 'herd mentality' witnessed following the announcemnt of cash raising required to further the company's ambitions.

regards

PTH

The Sunday Times article:

Biotech chief seeks to end years of pain
By Paul Durman
Alan Goodman of CeNeS hoped good results would change his luck, but he still needs more money



ALAN GOODMAN should be used to disappointment. As one of Britains most experienced biotechnology entrepreneurs, he is only too familiar with the ups and inevitable downs that go with the drug-development business.
Goodman was hoping that last week would mark a new beginning for CeNeS, his pain-treatment company that has endured a troubled three years.



My careers on the line, he said, as he prepared to announce results from late-stage trials of M6G, a treatment for post-operative pain.

I started this (treatment) based on work I discovered in 1992. This is the fruit of 12 years work, several millions of pounds, lots of trauma. Nobody else (in UK biotech) has got a compound from initial discovery through to phase III trials.

If weve got a result, I expect the mainline institutions to invest in it, to say: Jesus, theyve done it.

Last Monday, CeNeS duly announced positive results for M6G, a form of morphine developed to avoid causing the same level of nausea and vomiting.

Goodmans City advisers had hoped that shares in CeNeS would jump by as much as 25%. Instead, the shares weakened as the company said it was considering raising further equity to continue the development of its product.

Analysts close to CeNeS insisted that there was nothing alarming in this. Anyone who followed the company would have understood it needed to perform another phase III trial on M6G to compare it with the gold standard of morphine.

However, CeNeS has recently attracted some hot money from private investors who do not want to wait for a share placing. Hence the fall in the price.

CeNeS may need to raise 8m to 10m, or perhaps 15m if it seeks to avoid licensing M6G to international marketing partners.

Given the size of the market in post-operative pain, believers in the firm insist shares in CeNes look bloody cheap at below 10p. That values the company at only 25m.

CeNeS was briefly a stock- market high-flyer a specialist in pain and neurological disease that Goodman and his team built on the foundations of a moribund Scottish biotech company called Core.

His earlier ventures included the firms that became Chiroscience and Acambis two of the larger and more successful biotech companies to emerge in Britain over the past 15 years.

CeNeSs initial rapid progress came to a grinding halt in 2001. Apart from the collapse of investor confidence in biotech stocks, CeNeS found itself caught up in the severe financial problems and controversy afflicting two much larger drug companies, Elan and Bioglan.

CeNeS had licensed key products to Elan and Bioglan, which had previously been seen as highly successful, fast-growing and profitable businesses Elan was once Irelands most valuable company.

But, within months, both businesses started to unravel amid allegations of dubious accounting practices and exaggerated profits. Bioglan, a FTSE 250 company, quickly fell into administration while Elan embarked on a year-long restructuring programme to stave off insolvency.

That was the nightmare, said Goodman. A company with two major partners going bankrupt. Could we survive it or not? That was touch and go.

CeNeS had no choice but to embark on its own painful restructuring closing research facilities, shedding staff and selling off smaller products to concentrate on its pain treatments. The most important of these is M6G.

CeNeS has overcome numerous obstacles, and is close to delivering a valuable product. But Goodman still needs a bit more time and more money to complete the turnround.